ZAI LAB LIMITED Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current
ZAI LAB LIMITED (ZLAB) had Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current of $3.40 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Financing Receivable, Excluding Accrued Interest, after Allowance for Credit Loss, Current
us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossCurrent · last filed 2026-08-06
- 2026-06-30: Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current $3.40M.
- 2026-03-31: Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current $7.93M.
- 2025-12-31: Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current $12.17M.
- 2025-09-30: Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current $19.63M.
| Period end | Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current |
|---|---|
| 2026-06-30 | $3.40M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.93M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $12.17M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $19.63M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $10.84M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $11.12M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $4.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | $19.28M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $8.10M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $15.36M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $6.13M 10-K · filed 2025-02-27 |
| 2023-09-30 | $23.68M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $20.78M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $17.38M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $8.61M 10-K · filed 2024-02-27 |
| 2022-09-30 | $10.25M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $10.97M 10-Q · filed 2022-08-09 |
| 2021-12-31 | $7.33M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |